Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Hirschsprung Disease Treatment Market by Drug Class (Anti-infective, Antiemetic, Analgesics) and by End User (Hospitals      , Drug Stores, Retail Pharmacies, Mail Order Pharmacies  , Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A12655

Pages: NA

Charts: NA

Tables: NA

Hirschsprung disease is known to affect colon and cause problems with stool excretion. This disease is hereditary due to absence of a critical nerve cell in the muscle of a newborn baby’s colon. These nerve cells are known to control muscle contractions while food passes through the bowel. Due to absence of such contractions, stool accumulates in the colon. Symptoms of hirschsprung disease include swollen belly, diarrhea, and gastro intestinal issues. A few genetic factor that might possibly increase chances of the disease include having a sibling with the same disease, being born a male. Furthermore, it is associated with certain inherited conditions such as Down’s syndrome and congenital heart diseases. The disease can be treated through administration of prescribed doses of anti-infective, antiemetic, or analgesic drugs.

COVID-19 Impact Analysis

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future ,owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the hirschsprung disease treatment market.

Top Impacting Factors

  • The cause of hirschsprung disorder is multifactorial and largely hereditary. It is however liked to cardiovascular diseases and gastrointestinal abnormalities as well as subsequent rise in incidents of these diseases, which act as the major factor driving the growth of hirschsprung treatment market.
  • Technological advancements and subsequent increase in investments toward new product approvals and clinical drug trials to find advanced therapeutic ways to get rid of life-threatening diseases is yet another factor driving the market growth for hirschsprung disease treatment.
  • Continuous implementation of robust  policies by governments to develop new avenues for prevention, detection, and cure of such diseases is anticipated  to drive huge market gains around the globe.
  • However, frequent incidents of misdiagnosis of other syndromes such as type I sigmoid atresia as hirschsprung disease and the resulting bad word of mouth created is a huge factor visually hampering market growth.
  • Additionally, lack of awareness and associated misconception about advanced therapeutic drugs for treatment of hirschsprung and other fatal diseases coupled with lack of efficient healthcare services in third world economies is restricting market penetration.

Key Market Trends

  • Advanced stimulations in old technologies and avenues to treat hirschsprung disease coupled with rising disposable income and ability to spend of healthcare among general populace is anticipated to push Europe at the forefront of hirschsprung disease treatment market.
  • Unleashed wrath of COVID-19 and its exposure on Indian healthcare system are anticipated to bring in more foreign direct investments and regional players into the Indian healthcare system fray in the coming decade.
  • Surgery segment under hirschsprung treatment is anticipated to grow two-fold in revenue and volume, owing to established trust and positive past trends. Among surgeries, pull through surgery and ostomy are the most trending ones.
  • Recent studies conducted by University of Helsinki (UHS) concluded that about 1 in every 5000 babies in North America is born without enteric neurons in colon resulting in hirschsprung disease during adulthood. The disease is caused due to mutations in the RET receptor located at the surface of cell resulting in enlargement of colon and constipation in a few cases.
  • Children Hospital Los Angeles (CHLA) recently concluded a study promoting the idea of use of stem cells and genetic engineering to  treat newborn babies suffering from hirschsprung disease

Key Benefits of the Report

  • This study presents the analytical depiction of the hirschsprung disease treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Hirschsprung Disease Treatment Report

  • Which are the leading players active in the hirschsprung disease treatment market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the hirschsprung disease treatment market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is hirschsprung disease treatment?
  • What is the hirschsprung disease treatment market prediction in the future?
  • What are the current trends and predicted trends?

 Key Market Segments

  • By Drug Class
    • Anti-infective
    • Antiemetic
    • Analgesics
  • By End User
    • Hospitals      
    • Drug Stores
    • Retail Pharmacies
    • Mail Order Pharmacies  
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Astellas Pharma
  • Pfizer
  • Sanofi
  • Merck and Co.
  • Novartis AG
  • Cipla Ltd.
  • Johnson and Johnson
  • Bristol-Myers Squibb
  • Bayer Healthcare
  • Abbott

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: HIRSCHSPRUNG DISEASE TREATMENT MARKET, BY DRUG CLASS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Drug Class

    • 4.2. Anti-infective

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Antiemetic

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Analgesics

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: HIRSCHSPRUNG DISEASE TREATMENT MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals      

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Drug Stores

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Retail Pharmacies

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Mail Order Pharmacies  

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: HIRSCHSPRUNG DISEASE TREATMENT MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Drug Class

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Hirschsprung Disease Treatment Market

        • 6.2.5.1. Market Size and Forecast, By Drug Class
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Hirschsprung Disease Treatment Market

        • 6.2.6.1. Market Size and Forecast, By Drug Class
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Hirschsprung Disease Treatment Market

        • 6.2.7.1. Market Size and Forecast, By Drug Class
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Drug Class

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Hirschsprung Disease Treatment Market

        • 6.3.5.1. Market Size and Forecast, By Drug Class
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Hirschsprung Disease Treatment Market

        • 6.3.6.1. Market Size and Forecast, By Drug Class
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Hirschsprung Disease Treatment Market

        • 6.3.7.1. Market Size and Forecast, By Drug Class
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Hirschsprung Disease Treatment Market

        • 6.3.8.1. Market Size and Forecast, By Drug Class
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Hirschsprung Disease Treatment Market

        • 6.3.9.1. Market Size and Forecast, By Drug Class
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Hirschsprung Disease Treatment Market

        • 6.3.10.1. Market Size and Forecast, By Drug Class
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Hirschsprung Disease Treatment Market

        • 6.3.11.1. Market Size and Forecast, By Drug Class
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Drug Class

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Hirschsprung Disease Treatment Market

        • 6.4.5.1. Market Size and Forecast, By Drug Class
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Hirschsprung Disease Treatment Market

        • 6.4.6.1. Market Size and Forecast, By Drug Class
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Hirschsprung Disease Treatment Market

        • 6.4.7.1. Market Size and Forecast, By Drug Class
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Hirschsprung Disease Treatment Market

        • 6.4.8.1. Market Size and Forecast, By Drug Class
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Hirschsprung Disease Treatment Market

        • 6.4.9.1. Market Size and Forecast, By Drug Class
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Hirschsprung Disease Treatment Market

        • 6.4.10.1. Market Size and Forecast, By Drug Class
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Hirschsprung Disease Treatment Market

        • 6.4.11.1. Market Size and Forecast, By Drug Class
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Hirschsprung Disease Treatment Market

        • 6.4.12.1. Market Size and Forecast, By Drug Class
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Hirschsprung Disease Treatment Market

        • 6.4.13.1. Market Size and Forecast, By Drug Class
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Drug Class

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Hirschsprung Disease Treatment Market

        • 6.5.5.1. Market Size and Forecast, By Drug Class
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Hirschsprung Disease Treatment Market

        • 6.5.6.1. Market Size and Forecast, By Drug Class
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Hirschsprung Disease Treatment Market

        • 6.5.7.1. Market Size and Forecast, By Drug Class
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Hirschsprung Disease Treatment Market

        • 6.5.8.1. Market Size and Forecast, By Drug Class
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Hirschsprung Disease Treatment Market

        • 6.5.9.1. Market Size and Forecast, By Drug Class
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Hirschsprung Disease Treatment Market

        • 6.5.10.1. Market Size and Forecast, By Drug Class
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Pfizer

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Sanofi

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Bayer Healthcare

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Johnson And Johnson

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Merck And Co.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Novartis AG

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Bristol-Myers Squibb

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Astellas Pharma

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Abbott

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Cipla Ltd.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HIRSCHSPRUNG DISEASE TREATMENT MARKET, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR ANTI-INFECTIVE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR ANTIEMETIC, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR ANALGESICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL HIRSCHSPRUNG DISEASE TREATMENT MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR HOSPITALS      , BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR DRUG STORES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR RETAIL PHARMACIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR MAIL ORDER PHARMACIES  , BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL HIRSCHSPRUNG DISEASE TREATMENT MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA HIRSCHSPRUNG DISEASE TREATMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 15. U.S. HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 16. U.S. HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 17. CANADA HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 18. CANADA HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 20. MEXICO HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE HIRSCHSPRUNG DISEASE TREATMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 25. FRANCE HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 27. GERMANY HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. ITALY HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 29. ITALY HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 31. SPAIN HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. UK HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 33. UK HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 35. RUSSIA HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 37. REST OF EUROPE HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC HIRSCHSPRUNG DISEASE TREATMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 41. CHINA HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 42. CHINA HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 44. JAPAN HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. INDIA HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 46. INDIA HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 48. SOUTH KOREA HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 50. AUSTRALIA HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 52. THAILAND HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 54. MALAYSIA HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 56. INDONESIA HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA HIRSCHSPRUNG DISEASE TREATMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 63. BRAZIL HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH AFRICA HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 67. SAUDI ARABIA HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. UAE HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 69. UAE HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 71. ARGENTINA HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA HIRSCHSPRUNG DISEASE TREATMENT, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 73. REST OF LAMEA HIRSCHSPRUNG DISEASE TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. PFIZER: KEY EXECUTIVES
  • TABLE 75. PFIZER: COMPANY SNAPSHOT
  • TABLE 76. PFIZER: OPERATING SEGMENTS
  • TABLE 77. PFIZER: PRODUCT PORTFOLIO
  • TABLE 78. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. SANOFI: KEY EXECUTIVES
  • TABLE 80. SANOFI: COMPANY SNAPSHOT
  • TABLE 81. SANOFI: OPERATING SEGMENTS
  • TABLE 82. SANOFI: PRODUCT PORTFOLIO
  • TABLE 83. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. BAYER HEALTHCARE: KEY EXECUTIVES
  • TABLE 85. BAYER HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 86. BAYER HEALTHCARE: OPERATING SEGMENTS
  • TABLE 87. BAYER HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 88. BAYER HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 90. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 91. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 92. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 93. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. MERCK AND CO.: KEY EXECUTIVES
  • TABLE 95. MERCK AND CO.: COMPANY SNAPSHOT
  • TABLE 96. MERCK AND CO.: OPERATING SEGMENTS
  • TABLE 97. MERCK AND CO.: PRODUCT PORTFOLIO
  • TABLE 98. MERCK AND CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 100. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 101. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 102. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 103. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. BRISTOL-MYERS SQUIBB: KEY EXECUTIVES
  • TABLE 105. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 106. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
  • TABLE 107. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 108. BRISTOL-MYERS SQUIBB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. ASTELLAS PHARMA: KEY EXECUTIVES
  • TABLE 110. ASTELLAS PHARMA: COMPANY SNAPSHOT
  • TABLE 111. ASTELLAS PHARMA: OPERATING SEGMENTS
  • TABLE 112. ASTELLAS PHARMA: PRODUCT PORTFOLIO
  • TABLE 113. ASTELLAS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. ABBOTT: KEY EXECUTIVES
  • TABLE 115. ABBOTT: COMPANY SNAPSHOT
  • TABLE 116. ABBOTT: OPERATING SEGMENTS
  • TABLE 117. ABBOTT: PRODUCT PORTFOLIO
  • TABLE 118. ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. CIPLA LTD.: KEY EXECUTIVES
  • TABLE 120. CIPLA LTD.: COMPANY SNAPSHOT
  • TABLE 121. CIPLA LTD.: OPERATING SEGMENTS
  • TABLE 122. CIPLA LTD.: PRODUCT PORTFOLIO
  • TABLE 123. CIPLA LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL HIRSCHSPRUNG DISEASE TREATMENT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL HIRSCHSPRUNG DISEASE TREATMENT MARKET
  • FIGURE 3. SEGMENTATION HIRSCHSPRUNG DISEASE TREATMENT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN HIRSCHSPRUNG DISEASE TREATMENT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHIRSCHSPRUNG DISEASE TREATMENT MARKET
  • FIGURE 11. HIRSCHSPRUNG DISEASE TREATMENT MARKET SEGMENTATION, BY BY DRUG CLASS
  • FIGURE 12. HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR ANTI-INFECTIVE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR ANTIEMETIC, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR ANALGESICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. HIRSCHSPRUNG DISEASE TREATMENT MARKET SEGMENTATION, BY BY END USER
  • FIGURE 16. HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR HOSPITALS      , BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR DRUG STORES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR MAIL ORDER PHARMACIES  , BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. HIRSCHSPRUNG DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: HIRSCHSPRUNG DISEASE TREATMENT MARKET
  • FIGURE 27. TOP PLAYER POSITIONING, 2024
  • FIGURE 28. PFIZER: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. PFIZER: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. PFIZER: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. SANOFI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. SANOFI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. BAYER HEALTHCARE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. BAYER HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. BAYER HEALTHCARE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. MERCK AND CO.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. MERCK AND CO.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. MERCK AND CO.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. BRISTOL-MYERS SQUIBB: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. BRISTOL-MYERS SQUIBB: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. BRISTOL-MYERS SQUIBB: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. ASTELLAS PHARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. ASTELLAS PHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. ASTELLAS PHARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. ABBOTT: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. ABBOTT: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. ABBOTT: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. CIPLA LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. CIPLA LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. CIPLA LTD.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Hirschsprung Disease Treatment Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved